BETA
Your AI-Trained Oncology Knowledge Connection!
Elevating Community Oncology Care: Insights From World GU 2025
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.
Episode 13: Perspectives on Optimizing Community Care at World GU 2025
Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.
Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population
Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.
SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC
No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.
Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML
Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.
Episode 12: Variant Histology Treatment Considerations From World GU 2025
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Optimizing Care Planning for Variant Histology Populations at World GU 2025
At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.
Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC
After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.
Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC
Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.
Evaluating the Proximity and Impact of a Cure in Multiple Myeloma
According to Sundar Jagannath, MBBS, the cure for multiple myeloma was observed in patients who were cancer free for 5 years without maintenance therapy.
FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer
The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.
Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types
Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.
FDA Approves Selumetinib in Pediatric Neurofibromatosis Type 1
The FDA approved selumetinib as treatment for pediatric neurofibromatosis type 1, expanding options for young patients with inoperable plexiform neurofibromas.
Durvalumab Combo Enhances OS vs Chemo Alone in Treatment-Naive ES-SCLC
Rates of grade 3 or 4 AEs with durvalumab were similar across subgroups, with serious AEs more frequent in patients 70 years or older with ES-SCLC.
FDA Approves Gemcitabine Intravesical System in BCG-Unresponsive NMIBC
In patients who refuse or are ineligible for radical cystectomy, the gemcitabine intravesical system may be given after unsuccessful BCG treatment.
Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC
When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival in ALK-positive NSCLC.
IDE397 Combo Displays Promising Activity in MTAP-Deletion Urothelial Cancer
A manageable safety profile was observed across 2 expansion doses of the combination in urothelial cancer, consistent with known adverse effects of both drugs.
ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives
THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.
Frontline Aumolertinib/Chemo Yields PFS Superiority in EGFR+ NSCLC
Adding aumolertinib to chemotherapy in the treatment of patients with EGFR-mutated NSCLC led to improvements in progression-free survival.
Evaluating the Evolution of Myelodysplastic Syndrome Diagnostic Criteria
Morphological dysplasia is the cornerstone of making a myelodysplastic syndrome diagnosis, except for a few myelodysplastic syndrome–defining genetic alterations.
Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets
The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.
Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC
For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.
Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC
The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.
Zidesamtinib Exhibits Durable Activity in Pretreated ROS1+ Advanced NSCLC
Zidesamtinib was well tolerated in patients who received prior ROS1 TKI therapy with advanced NSCLC, and dose discontinuation/reduction rates were low.
Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC
Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.
Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions
Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.
Perioperative Pembrolizumab Combo Improves Responses in NSCLC Subgroups
Subgroup data from KEYNOTE-671 support the use of perioperative pembrolizumab in stage II or III non–small cell lung cancer of any clinical nodal status.
Osimertinib Combo Exhibits OS Improvement in EGFR-Mutated Advanced NSCLC
AE-related discontinuations of osimertinib were low, and no new treatment-related deaths were reported with the combination in EGFR-mutant NSCLC.
The Clinical Implications of Having a “Cure” in Multiple Myeloma
Sundar Jagannath, MBBS, said that when a cure is defined for patients with multiple myeloma, specific patients may be able to stop therapy without a risk of relapsing.
Cardiovascular Considerations in Breast Cancer Treatment and Survivorship
Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
